Prophylaxis News and Research

RSS

Doctors debate use of blood thinners to prevent clots in women after C-sections

Nearly all women who deliver babies through cesarean section at Columbia University Irving Medical Center in New York City receive injections of the blood thinner heparin for weeks after the procedure, to prevent potentially life-threatening blood clots.

17 Mar 2021

Cross-national study associates low vitamin D levels with higher COVID-19-related mortality

A new study by an international team of researchers – from New York University, Abu Dhabi, the Ludwig-Maximilians-Universität, München, and Barts Cancer Institute, London – showed that there are lower COVID-19 mortality rates in countries with the most insufficient annual sun exposure, but highest mean 25-hydroxyvitamin D (25(OH)D) or vitamin D (25)-HD levels.

16 Mar 2021

Scientists increase potency of HIV-1 antibody, identify new ways to develop vaccines

Much like coronavirus, circulating HIV-1 viruses mutate into diverse variants that pose challenges for scientists developing vaccines to protect people from HIV/AIDS.

12 Mar 2021

NIAID awards $2.5 million in grants to support research on bacteriophage therapy

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded $2.5 million in grants to 12 institutes around the world to support research on bacteriophage therapy.

11 Mar 2021

Researchers develop ultrapotent miniproteins that target SARS-CoV-2 receptor-binding domain

Researchers have investigated the effectiveness of a bioengineered miniprotein in protecting against SARS-CoV-2 infection in vivo. The researchers evaluated the miniprotein, LCB1, against SARS-CoV-2-mediated lung disease in human ACE2-expressing transgenic mice.

3 Mar 2021

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Researchers have developed a stable and ultrapotent homotrimeric Pittsburgh inhalable Nanobody 21 (PiN-21) against SARS-CoV-2 infection in Syrian hamsters. They demonstrated the high therapeutic efficacy of this homotrimeric Nb, leveraging both intranasal and aerosol delivery.

26 Feb 2021

Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus

A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults.

23 Feb 2021

Mucosal delivery of IFNs a good strategy for COVID-19 prophylaxis post-exposure

Researchers from the UK and Germany recently reported a comprehensive characterization of the SARS-CoV-2 response of human nasal epithelial cells, revealing a response dominated by IFN-I/IIIs. Also, recombinant IFN-I/III treatment was found to efficiently block the replication of SARS-CoV-2, which suggests that mucosal delivery of IFNs may be a good strategy for prophylaxis post-exposure.

22 Feb 2021

Engineered peptide can reduce severe COVID-19 infection in humans

An engineered peptide given to ferrets two days before they were co-housed with SARS-CoV-2-infected animals prevented virus transmission to the treated ferrets, a new study shows.

18 Feb 2021

Echocardiographic screening for early detection of rheumatic heart disease in schools

Rheumatic heart disease (RHD) develops as a long term complication of childhood streptococcal angina. Latent RHD can be detected with echocardiography years before it becomes symptomatic. RHD is curable when treated early with medication.

11 Feb 2021

Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection

Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.

10 Feb 2021

Pediatric trial results show rabies treatment is safe and effective in children

A treatment, known as KEDRAB (Rabies Immune Globulin [Human]), currently used in the prevention of rabies has been demonstrated to be safe and effective for patients age 17 and under.

10 Feb 2021

Viral load the main driver of SARS-CoV-2 transmission

A study conducted by researchers in the UK and Spain suggests that viral load is the main determinant of transmission risk in cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

3 Feb 2021

Researchers report trial results of rectal microbicides at HIV R4P Virtual Conference

Researchers seeking to develop on-demand and behaviorally congruent HIV prevention options for people who practice anal sex are reporting the results of three early phase clinical trials of rectal microbicides at this week's HIV Research for Prevention (HIV R4P) Virtual Conference.

3 Feb 2021

Medicaid expansion helps detect more numbers of undiagnosed HIV infections

The Medicaid expansion facilitated by the Affordable Care Act led to increases in the identification of undiagnosed HIV infections and in the use of HIV prevention services such as preexposure prophylaxis drugs, says new research co-written by a team of University of Illinois Urbana-Champaign experts who study the intersection of health care and public policy.

27 Jan 2021

High factor V levels linked to lymphopenia and weakened immunity in severe COVID-19

A new study suggests that factor V, a coagulation factor, is upregulated in a range of white blood cells in severe COVID-19. This increase is linked to the observed coagulopathy, lymphopenia and suppression of adaptive immunity in such patients.

21 Jan 2021

New clinical practice guidelines on diagnosis, management of von Willebrand Disease

The American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH) have developed joint clinical practice guidelines on the diagnosis and management of von Willebrand Disease (VWD), the world's most common inherited bleeding disorder. The guidelines were published today in Blood Advances.

13 Jan 2021

Researchers pinpoint spike protein regions as targets for passive and active COVID-19 vaccines

Researchers at Stanford University School of Medicine have identified regions of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have relatively few mutations and might therefore serve as important targets for prophylactic agents against coronavirus disease 2019 (COVID-19).

10 Jan 2021

Potential role of chitinase 3-like-1 in severity of COVID-19

Now, an intriguing preprint research paper on the bioRxiv server reports the identification of an enzyme called chitinase 3-like-1 (CHI3L1) that mediates this age-dependent impact of the virus and could serve as a powerful therapeutic approach in mitigating the severity of COVID-19 in this high-risk group.

7 Jan 2021

Study explores women's interest in long-acting injectable antiretroviral therapy

A study led by Columbia University Mailman School of Public Health researchers examines attitudes toward long-acting injectable (LAI) HIV therapies, among women with a history of injection--including medical purposes and substance use. The findings appear in the journal AIDS Patient Care and STDs.